Emergent BioSolutions (CGT)

Baltimore, MD

Hybrid — also manufactures internal programs

AAV Adenoviral

4 confirmed programs · 1 sponsors · Last scored 2026-03-15

73.0

Signal Score

○ FDA Inspections ✓ Clinical Trials (4) ○ SEC Filings ○ Press

Quick Facts: Emergent BioSolutions (CGT)

Signal Score: 73.0/100 (as of 2026-03-15)
Quality Compliance: Assessment pending
Headquarters: Baltimore, MD
Modalities: AAV, Adenoviral
Active CGT Programs: 4 confirmed from ClinicalTrials.gov across 1 sponsors
Data Sources: FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By: CDMO Signal — independent CGT manufacturing intelligence platform

Quality Compliance —

No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.

FDA InspectionsNo US records on file

No FDA inspection records found for this manufacturer

Quality score requires FDA inspection data

Operations —

No ClinicalTrials.gov facility matches confirmed for this manufacturer.

Programs 4

Sponsors1

ModalitiesAAV, Adenoviral

4 active programs across 1 sponsors

Modalities: Adenoviral, AAV

2 programs in advanced phases (Phase 2/3)

Source: ClinicalTrials.gov facility matching

NCT03160339 A Study to Assess the Safety, Pharmacodynamics, and... PHASE1 Terminated

NCT01979406 A Phase 1 Ascending Dose Study to Assess the Safety and... PHASE1 Completed

NCT00893516 CD4 in Combination With CHOP in Treating Non-cutaneous... PHASE2 Terminated

NCT00877656 HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma PHASE2/PHASE3 Completed

Source: ClinicalTrials.gov · Retrieved Mar 20, 2026

Financial Stability

Subsidiary of Emergent BioSolutions

SEC FilingsParent: Emergent BioSolutions

Publicly traded — financial transparency

Capacity

2 CGT manufacturing sites

Source: ClinicalTrials.gov · Retrieved Mar 20, 2026

Represent this organization? Contact us to verify or update this profile.

See all CDMOs in:

AAV CDMOs → Adenoviral CDMOs →